NEW YORK, Sept. 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Markets for Enzyme Inhibitors -- Focus on the US
http://www.reportlinker.com/p0919320/Global-Markets-for-Enzyme-Inhibitors----Focus-on-the-US.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
INTRODUCTION
STUDY GOALS AND OBJECTIVES
The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.
This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. The improvements in the market and the setbacks and needs of the market are discussed in this report. The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.
A detailed analysis of the enzyme inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.
Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.
REASONS FOR DOING THE STUDY
Extensive research in the field of enzyme inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of enzyme inhibitors in their productions and processes. This has led to steady market growth for enzyme inhibitors.
Research and development (R&D) spending, along with increasing competition, patent expirations and new technologies, is directing this to a new level. Although, due to patent expirations, the overall revenue for the market has decreased slightly from 2009 to 2011, new advancements, new product launches and the changing lifestyle will cause the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
This report provides invaluable information to manufacturers and users of PPIs, protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, PDE5 inhibitors, neuraminidase inhibitors, and ACE inhibitors. Pharmaceutical and biotechnology companies, research institutes, and physicians will find this study to be of interest.
SCOPE OF REPORT
The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry. BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.
METHODOLOGY AND INFORMATION SOURCES
BCC conducted a comprehensive literature search, which included technical newsletters and journals. The data were collected through interviews and correspondence with technical experts manufacturing enzyme inhibitors. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. The data were carefully collected from various industry sources. BCC spoke with officials within the industry and consulted newsletters; company and product literature; and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, the data were compiled from current financial, trade and government sources.
ANALYST CREDENTIALS
The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Dewan was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy, An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.
The lead consultant for this project is Dr. Kapil A. Setia, who has a doctorate in life sciences. She has a number of research publications in her credit, including her thesis on "Studies on Phenotypic Variation, Clonal Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.)," which was given an award of excellence.
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE 1
SCOPE OF REPORT 2
METHODOLOGY AND INFORMATION SOURCES 2
ANALYST CREDENTIALS 2
RELATED REPORTS 3
BCC ON-LINE SERVICES 3
DISCLAIMER 3
CHAPTER 2 SUMMARY 5
SUMMARY TABLE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016 ($
MILLIONS) 5
SUMMARY FIGURE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016 ($
MILLIONS) 6
CHAPTER 3 OVERVIEW 8
DEFINITIONS 8
STRUCTURE OF ENZYMES 8
ACTIVATION ENERGY 8
SPECIFICITY 8
ENZYME SUBSTRATE INTERACTION 9
CONDITIONS OF ENZYME ACTION 9
CLASSIFICATION OF ENZYMES 9
OXIDOREDUCTASES 10
TRANSFERASES 10
HYDROLASES 10
NUCLEASES 11
PHOSPHATASES 11
LYASES 11
ISOMERASES 11
LIGASES 11
REAL-LIFE APPLICATIONS OF ENZYMES 11
METABOLIC ENZYMES 12
DIGESTIVE ENZYMES 13
FOOD ENZYMES 14
NEED FOR ENZYMES IN HUMAN BODY 14
PROTEOLYTIC ENZYMES 14
LIPOLYTIC ENZYMES 15
AMYLOLYTIC ENZYMES 15
RENNIN ENZYMES 15
WHAT ARE ENZYME INHIBITORS 15
WHY ENZYME INHIBITION 15
USE OF ENZYME INHIBITORS 16
MECHANISM OF ENZYME INHIBITION 16
TYPES OF ENZYME INHIBITORS 16
MIXED INHIBITION 17
COMPETITIVE INHIBITION 17
CLASSIFICATION OF ENZYME INHIBITORS 17
TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 17
OXIDOREDUCTASE INHIBITORS 18
ALDOSE REDUCTASE INHIBITORS 18
STATINS 19
HISTORY OF DEVELOPMENT OF STATINS 19
TABLE 2 HISTORY OF DEVELOPMENT OF STATINS 19
5-ALPHA-REDUCTASE INHIBITORS 19
AROMATASE INHIBITORS 20
COX-2 INHIBITORS 20
HYDROLASE INHIBITORS 20
NEURAMINIDASE INHIBITORS 20
PROTEASE INHIBITORS 21
TABLE 3 HISTORY OF DISCOVERY OF PROTEASE INHIBITORS 21
PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 22
PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS 22
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 22
TABLE 4 DEVELOPMENT OF ACE INHIBITORS 23
PROTON PUMP INHIBITORS 23
TRANSFERASE INHIBITORS 23
PROTEIN KINASE INHIBITORS 23
REVERSE TRANSCRIPTASE INHIBITORS 24
CHAPTER 4 REGULATORY ASPECTS 26
TABLE 5 NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011 26
TABLE 6 NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS 29
TABLE 7 SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011 30
CHAPTER 5 MARKET LEADERS AND THEIR PRODUCTS FOR ENZYME INHIBITORS 34
TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS 34
TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS 34
TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS 35
TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF STATINS 35
TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS 36
TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE
INHIBITORS 36
TABLE 14 LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS 37
TABLE 15 LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS 38
TABLE 16 LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS 38
CHAPTER 6 NEW DEVELOPMENTS 41
TABLE 17 CLINICAL TRIALS ENZYME INHIBITORS 41
TABLE 18 CLINICAL TRIALS OF STATINS 42
TABLE 19 CLINICAL TRIALS FOR AROMATASE INHIBITORS 44
TABLE 20 CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS 44
TABLE 21 CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS 47
TABLE 22 CLINICAL TRIALS FOR PDE5 INHIBITORS 51
TABLE 23 CLINICAL TRIALS FOR PDE4 INHIBITORS 52
TABLE 24 CLINICAL TRIALS FOR PROTEASE INHIBITORS 53
TABLE 25 CLINICAL TRIALS FOR ACE INHIBITORS 53
TABLE 26 CLINICAL TRIALS FOR PROTON PUMP INHIBITORS 55
NEW DRUGS IN CLINICAL TRIALS 56
TABLE 27 NEW ENZYME INHIBITORS IN CLINICAL TRIALS 56
CHAPTER 7 GLOBAL MARKETS 58
MARKET ANALYSIS 58
TABLE 28 GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 59
FIGURE 1 GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 59
PROTON PUMP INHIBITORS 60
MARKET OVERVIEW 60
MARKET REVENUE 61
TABLE 29 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($ MILLIONS) 61
FIGURE 2 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 62
PROTEASE INHIBITORS 62
MARKET OVERVIEW 62
MARKET REVENUE 63
TABLE 30 GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 64
FIGURE 3 GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 64
REVERSE TRANSCRIPTASE INHIBITORS 64
MARKET OVERVIEW 65
MARKET REVENUE 66
TABLE 31 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 66
FIGURE 4 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($
MILLIONS) 66
KINASE INHIBITORS 67
MARKET OVERVIEW 67
MARKET REVENUE 69
TABLE 32 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 69
FIGURE 5 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 69
STATINS 70
MARKET OVERVIEW 71
MARKET REVENUE 72
TABLE 33 GLOBAL MARKET FOR STATINS, THROUGH 2016 ($ MILLIONS) 72
FIGURE 6 GLOBAL MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 72
AROMATASE INHIBITORS 73
MARKET OVERVIEW 73
MARKET REVENUE 74
TABLE 34 GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 74
FIGURE 7 GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 74
PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 75
MARKET OVERVIEW 75
MARKET REVENUE 76
TABLE 35 GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 77
FIGURE 8 GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 77
NEURAMINIDASE INHIBITORS 77
MARKET OVERVIEW 78
MARKET REVENUE 78
TABLE 36 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 78
FIGURE 9 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($ MILLIONS) 78
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 79
MARKET OVERVIEW 80
MARKET REVENUE 80
TABLE 37 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 81
FIGURE 10 GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 81
MARKET SHARES 81
TABLE 38 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82
FIGURE 11 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82
TABLE 39 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 ($ MILLIONS) 82
FIGURE 12 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82
TABLE 40 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83
FIGURE 13 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83
TABLE 41 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84
FIGURE 14 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84
TABLE 42 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
FIGURE 15 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
TABLE 43 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
FIGURE 16 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
TABLE 44 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86
FIGURE 17 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86
TABLE 45 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87
FIGURE 18 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87
TABLE 46 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 88
FIGURE 19 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 88
MARKET BY APPLICATIONS 88
TABLE 47 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE
SECTORS, THROUGH 2016 ($ MILLIONS) 89
FIGURE 20 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/
DISEASE SECTORS, 2009-2016 ($ MILLIONS) 89
CARDIOVASCULAR (CV) DISEASE 90
TABLE 48 GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,
THROUGH 2016 ($ MILLIONS) 91
FIGURE 21 GLOBAL MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,
2009-2016 ($ MILLIONS) 91
GASTROINTESTINAL DISORDERS 91
TABLE 49 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
THROUGH 2016 ($ MILLIONS) 92
FIGURE 22 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
2009-2016 ($ MILLIONS) 92
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 93
TABLE 50 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($
MILLIONS) 94
FIGURE 23 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($ MILLIONS) 94
HEPATITIS 95
TABLE 51 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($
MILLIONS) 96
FIGURE 24 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($
MILLIONS) 96
CANCER 97
TABLE 52 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH
2016 ($ MILLIONS) 99
FIGURE 25 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016 ($
MILLIONS) 99
ERECTILE DYSFUNCTION (ED) 99
TABLE 53 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
THROUGH 2016 ($ MILLIONS) 100
FIGURE 26 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
2009-2016 ($ MILLIONS) 100
OTHERS 101
TABLE 54 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016
($ MILLIONS) 102
FIGURE 27 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016 ($
MILLIONS) 102
GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION 102
TABLE 55 GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010 (%) 102
FIGURE 28 GLOBAL MARKET SHARE OF TECHNICAL ENZYMES, 2010 (%) 103
CHAPTER 8 MARKETS IN THE UNITED STATES 105
MARKET ANALYSIS 105
TABLE 56 U.S. MARKET FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 105
FIGURE 29 U.S. MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 106
PROTON PUMP INHIBITORS (PPI) 107
MARKET OVERVIEW 107
MARKET REVENUE 108
TABLE 57 U.S. MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($ MILLIONS) 108
FIGURE 30 U.S. MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 108
PROTEASE INHIBITORS 109
MARKET OVERVIEW 109
MARKET REVENUE 110
TABLE 58 U.S. MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 111
FIGURE 31 U.S. MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 111
REVERSE TRANSCRIPTASE INHIBITORS 111
MARKET OVERVIEW 111
MARKET REVENUE 112
TABLE 59 U.S. MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 112
FIGURE 32 U.S. MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($
MILLIONS) 113
KINASE INHIBITORS 113
MARKET OVERVIEW 113
MARKET REVENUE 115
TABLE 60 U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 115
FIGURE 33 U.S. MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 115
STATINS 115
MARKET OVERVIEW 116
MARKET REVENUE 117
TABLE 61 U.S. MARKET FOR STATINS, THROUGH 2016 ($ MILLIONS) 117
FIGURE 34 U.S. MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 117
AROMATASE INHIBITORS 118
MARKET OVERVIEW 118
MARKET REVENUE 119
TABLE 62 U.S. MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 119
FIGURE 35 U.S. MARKET FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 119
PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 120
MARKET OVERVIEW 120
MARKET REVENUE 120
TABLE 63 U.S. MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 121
FIGURE 36 U.S. MARKET FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 121
NEURAMINIDASE INHIBITORS 121
MARKET OVERVIEW 122
MARKET REVENUE 122
TABLE 64 U.S. MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 122
FIGURE 37 U.S. MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($ MILLIONS) 122
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 123
MARKET OVERVIEW 123
MARKET REVENUE 124
TABLE 65 U.S. MARKET FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 124
FIGURE 38 U.S. MARKET FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 125
MARKET SHARES OF INDUSTRY LEADERS IN THE UNITED STATES 125
PROTON PUMP INHIBITORS 125
TABLE 66 U.S. MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010 (%) 126
FIGURE 39 U.S. MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010 (%) 126
PROTEASE INHIBITORS 126
TABLE 67 U.S. MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010 (%) 127
FIGURE 40 U.S. MARKET SHARES OF PROTEASE INHIBITORS MANUFACTURERS, 2010 (%) 127
KINASE INHIBITORS 127
TABLE 68 U.S. MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010 (%) 128
FIGURE 41 U.S. MARKET SHARES OF KINASE INHIBITORS MANUFACTURERS, 2010 (%) 128
STATINS 128
TABLE 69 U.S. MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%) 128
FIGURE 42 U.S. MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%) 129
AROMATASE INHIBITORS 129
TABLE 70 U.S. MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010 (%) 130
FIGURE 43 U.S. MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010 (%) 130
REVERSE TRANSCRIPTASE INHIBITORS 130
TABLE 71 U.S. MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR
MANUFACTURERS, 2010 (%) 130
FIGURE 44 U.S. MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR
MANUFACTURERS, 2010 (%) 131
PDE5 INHIBITORS 131
TABLE 72 U.S. MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010 (%) 131
FIGURE 45 U.S. MARKET SHARES OF PDE5 MANUFACTURERS, 2010 (%) 132
NEURAMINIDASE INHIBITORS 132
TABLE 73 U.S. MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010
(%) 132
FIGURE 46 U.S. MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010 (%) 132
ACE INHIBITORS 133
TABLE 74 U.S. MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 133
FIGURE 47 U.S. MARKET SHARES OF ACE MANUFACTURERS, 2010 (%) 133
MARKET BY APPLICATIONS 134
TABLE 75 U.S. ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE
SECTORS, THROUGH 2016 ($ MILLIONS) 135
FIGURE 48 U.S. MARKET INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE
SECTORS, 2009-2016 ($ MILLIONS) 135
CARDIOVASCULAR (CV) DISEASES 136
TABLE 76 U.S. MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, THROUGH
2016 ($ MILLIONS) 137
FIGURE 49 U.S. MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,
2009-2016 ($ MILLIONS) 137
GASTROINTESTINAL DISORDERS 138
TABLE 77 U.S. MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
THROUGH 2016 ($ MILLIONS) 138
FIGURE 50 U.S. MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
2009-2016 ($ MILLIONS) 138
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 139
TABLE 78 U.S. MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($ MILLIONS) 140
FIGURE 51 U.S. MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($ MILLIONS) 140
HEPATITIS 140
TABLE 79 U.S. MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($
MILLIONS) 142
FIGURE 52 U.S. MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($ MILLIONS) 142
CANCER 142
TABLE 80 U.S. MARKET OF ENZYME INHIBITORS IN VARIOUS CANCER, THROUGH 2016 ($
MILLIONS) 144
FIGURE 53 U.S. MARKET OF ENZYME INHIBITORS IN VARIOUS CANCER, 2009-2016 ($
MILLIONS) 144
ERECTILE DYSFUNCTION 144
TABLE 81 U.S. MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH
2016 ($ MILLIONS) 145
FIGURE 54 U.S. MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016
($ MILLIONS) 145
OTHERS 146
TABLE 82 U.S. MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016 ($
MILLIONS) 147
FIGURE 55 U.S. MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016 ($
MILLIONS) 147
CHAPTER 9 PATENT ANALYSIS 149
PATENTS BY YEAR 149
TABLE 83 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012 149
FIGURE 56 NUMBER OF PATENTS BY YEAR, 2008–2012 149
FIGURE 57 NUMBER OF PATENTS BY YEAR, 2008-2012 (%) 150
PATENTS BY TYPE 150
TABLE 84 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008-2012 151
FIGURE 58 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–2012 151
PATENTS BY COMPANY 151
TABLE 85 NUMBER OF U.S. PATENTS BY COMPANY FOR ENZYME INHIBITORS, 2008-2012 152
PATENTS BY COUNTRY 153
TABLE 86 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,
2008-2012 153
FIGURE 59 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,
2008–2012 154
TABLE 87 PATENT SHARES BY COUNTRY FOR INDUSTRIAL ENZYMES, 2008-2012 (%) 155
FIGURE 60 PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008-2012 (%) 155
PATENTS BY ASSIGNEE 155
TABLE 88 PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008-2012 156
FIGURE 61 PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008–2012 (%) 156
CHAPTER 10 CURRENT SITUATION 158
MARKET CONDITIONS 158
UNITED STATES 158
EUROPE 158
EMERGING MARKETS 158
TRENDS AND ISSUES IN ENZYME INHIBITORS MARKET 159
COMPETITION 159
PATENT EXPIRATIONS 159
UPCOMING PATENT EXPIRATIONS/UPCOMING PATENT CLIFF 159
PATENT CHALLENGES / LEGAL PROCEEDINGS 159
NEW INDICATIONS APPROVED 160
NEW DRUG APPROVALS 160
RX- TO- OTC SWITCH 161
INCREASING NUMBER OF BABY BOOMERS 161
MERGERS AND ACQUISITIONS AND ALLIANCES 161
DIRECT-TO-CONSUMER ADVERTISING 162
CHAPTER 11 COMPANY PROFILES 164
ABBOTT LABORATORIES 164
AMGEN INC. 164
ASTRAZENECA PLC 165
AUROBINDO PHARMA 165
BAYER HEALTHCARE PHARMACEUTICALS 165
BOEHRINGER INGELHEIM GMBH 166
BRISTOL-MYERS SQUIBB 166
CIPLA LTD. 167
DR. REDDY'S LABORATORIES LTD. 167
EISAI INC. 168
ELI LILLY & CO. 168
ENDO PHARMACEUTICALS 169
GILEAD SCIENCES INC. 169
GLAXOSMITHKLINE PLC 169
GLENMARK GENERICS LTD. 170
HETERO DRUGS LTD. 171
HOFFMAN-LA ROCHE LTD. 171
INCYTE CORP. 171
JOHNSON & JOHNSON 172
LUPIN PHARMACEUTICALS INC. 172
MERCK & CO. INC. 173
MERCK SERONO SA 174
MYLAN LABORATORIES INC. 174
MYLAN LABORATORIES LTD. 175
NOVARTIS AG 175
NOVARTIS NORTH AMERICA 175
OSI PHARMACEUTICALS LLC 176
PAR PHARMACEUTICAL COMPANIES INC. 176
PFIZER INC. 177
RANBAXY LABORATORIES LTD. 177
ROXANE LABORATORIES LTD. 178
SANDOZ 178
SANOFI-AVENTIS 179
SANTARUS INC. 179
SUN PHARMACEUTICALS 180
TAKEDA PHARMACEUTICAL CO. LTD. 180
TEVA PHARMACEUTICAL INDUSTRIES LTD. 180
VERTEX PHARMACEUTICALS 181
VIIV HEALTHCARE 181
WATSON PHARMACEUTICALS INC. 182
CHAPTER 12 APPENDIX—ABBREVIATIONS 184
LIST OF TABLES
SUMMARY TABLE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016 ($
MILLIONS) 5
TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 17
TABLE 2 HISTORY OF DEVELOPMENT OF STATINS 19
TABLE 3 HISTORY OF DISCOVERY OF PROTEASE INHIBITORS 21
TABLE 4 DEVELOPMENT OF ACE INHIBITORS 23
TABLE 5 NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011 26
TABLE 6 NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS 29
TABLE 7 SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011 30
TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS 34
TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS 34
TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS 35
TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF STATINS 35
TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS 36
TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE
INHIBITORS 36
TABLE 14 LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS 37
TABLE 15 LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS 38
TABLE 16 LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS 38
TABLE 17 CLINICAL TRIALS ENZYME INHIBITORS 41
TABLE 18 CLINICAL TRIALS OF STATINS 42
TABLE 19 CLINICAL TRIALS FOR AROMATASE INHIBITORS 44
TABLE 20 CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS 44
TABLE 21 CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS 47
TABLE 22 CLINICAL TRIALS FOR PDE5 INHIBITORS 51
TABLE 23 CLINICAL TRIALS FOR PDE4 INHIBITORS 52
TABLE 24 CLINICAL TRIALS FOR PROTEASE INHIBITORS 53
TABLE 25 CLINICAL TRIALS FOR ACE INHIBITORS 53
TABLE 26 CLINICAL TRIALS FOR PROTON PUMP INHIBITORS 55
TABLE 27 NEW ENZYME INHIBITORS IN CLINICAL TRIALS 56
TABLE 28 GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 59
TABLE 29 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($ MILLIONS) 61
TABLE 30 GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 64
TABLE 31 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 66
TABLE 32 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 69
TABLE 33 GLOBAL MARKET FOR STATINS, THROUGH 2016 ($ MILLIONS) 72
TABLE 34 GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 74
TABLE 35 GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 77
TABLE 36 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 78
TABLE 37 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 81
TABLE 38 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82
TABLE 39 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 ($ MILLIONS) 82
TABLE 40 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83
TABLE 41 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84
TABLE 42 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
TABLE 43 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
TABLE 44 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86
TABLE 45 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87
TABLE 46 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 88
TABLE 47 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE
SECTORS, THROUGH 2016 ($ MILLIONS) 89
TABLE 48 GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,
THROUGH 2016 ($ MILLIONS) 91
TABLE 49 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
THROUGH 2016 ($ MILLIONS) 92
TABLE 50 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($
MILLIONS) 94
TABLE 51 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($
MILLIONS) 96
TABLE 52 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016
($ MILLIONS) 99
TABLE 53 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
THROUGH 2016 ($ MILLIONS) 100
TABLE 54 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016 ($
MILLIONS) 102
TABLE 55 GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010 (%) 102
TABLE 56 U.S. MARKET FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 105
TABLE 57 U.S. MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($ MILLIONS) 108
TABLE 58 U.S. MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 111
TABLE 59 U.S. MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 112
TABLE 60 U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 115
TABLE 61 U.S. MARKET FOR STATINS, THROUGH 2016 ($ MILLIONS) 117
TABLE 62 U.S. MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 119
TABLE 63 U.S. MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 121
TABLE 64 U.S. MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 122
TABLE 65 U.S. MARKET FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 124
TABLE 66 U.S. MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010 (%) 126
TABLE 67 U.S. MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010 (%) 127
TABLE 68 U.S. MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010 (%) 128
TABLE 69 U.S. MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%) 128
TABLE 70 U.S. MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010 (%) 130
TABLE 71 U.S. MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR
MANUFACTURERS, 2010 (%) 130
TABLE 72 U.S. MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010 (%) 131
TABLE 73 U.S. MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010 (%) 132
TABLE 74 U.S. MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 133
TABLE 75 U.S. ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE
SECTORS, THROUGH 2016 ($ MILLIONS) 135
TABLE 76 U.S. MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, THROUGH
2016 ($ MILLIONS) 137
TABLE 77 U.S. MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
THROUGH 2016 ($ MILLIONS) 138
TABLE 78 U.S. MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($ MILLIONS) 140
TABLE 79 U.S. MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($ MILLIONS) 142
TABLE 80 U.S. MARKET OF ENZYME INHIBITORS IN VARIOUS CANCER, THROUGH 2016 ($
MILLIONS) 144
TABLE 81 U.S. MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH
2016 ($ MILLIONS) 145
TABLE 82 U.S. MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016 ($
MILLIONS) 147
TABLE 83 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012 149
TABLE 84 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008-2012 151
TABLE 85 NUMBER OF U.S. PATENTS BY COMPANY FOR ENZYME INHIBITORS, 2008-2012 152
TABLE 86 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,
2008-2012 153
TABLE 87 PATENT SHARES BY COUNTRY FOR INDUSTRIAL ENZYMES, 2008-2012 (%) 155
TABLE 88 PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008-2012 156
LIST OF FIGURES
SUMMARY FIGURE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016 ($
MILLIONS) 6
FIGURE 1 GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 59
FIGURE 2 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 62
FIGURE 3 GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 64
FIGURE 4 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($
MILLIONS) 66
FIGURE 5 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 69
FIGURE 6 GLOBAL MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 72
FIGURE 7 GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 74
FIGURE 8 GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 77
FIGURE 9 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($ MILLIONS) 78
FIGURE 10 GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 81
FIGURE 11 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82
FIGURE 12 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82
FIGURE 13 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83
FIGURE 14 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84
FIGURE 15 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
FIGURE 16 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
FIGURE 17 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86
FIGURE 18 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87
FIGURE 19 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 88
FIGURE 20 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE
SECTORS, 2009-2016 ($ MILLIONS) 89
FIGURE 21 GLOBAL MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,
2009-2016 ($ MILLIONS) 91
FIGURE 22 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
2009-2016 ($ MILLIONS) 92
FIGURE 23 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($ MILLIONS) 94
FIGURE 24 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($ MILLIONS) 96
FIGURE 25 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016 ($
MILLIONS) 99
FIGURE 26 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
2009-2016 ($ MILLIONS) 100
FIGURE 27 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016 ($
MILLIONS) 102
FIGURE 28 GLOBAL MARKET SHARE OF TECHNICAL ENZYMES, 2010 (%) 103
FIGURE 29 U.S. MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 106
FIGURE 30 U.S. MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 108
FIGURE 31 U.S. MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 111
FIGURE 32 U.S. MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($
MILLIONS) 113
FIGURE 33 U.S. MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 115
FIGURE 34 U.S. MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 117
FIGURE 35 U.S. MARKET FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 119
FIGURE 36 U.S. MARKET FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 121
FIGURE 37 U.S. MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($ MILLIONS) 122
FIGURE 38 U.S. MARKET FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 125
FIGURE 39 U.S. MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010 (%) 126
FIGURE 40 U.S. MARKET SHARES OF PROTEASE INHIBITORS MANUFACTURERS, 2010 (%) 127
FIGURE 41 U.S. MARKET SHARES OF KINASE INHIBITORS MANUFACTURERS, 2010 (%) 128
FIGURE 42 U.S. MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%) 129
FIGURE 43 U.S. MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010 (%) 130
FIGURE 44 U.S. MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR
MANUFACTURERS, 2010 (%) 131
FIGURE 45 U.S. MARKET SHARES OF PDE5 MANUFACTURERS, 2010 (%) 132
FIGURE 46 U.S. MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010 (%) 132
FIGURE 47 U.S. MARKET SHARES OF ACE MANUFACTURERS, 2010 (%) 133
FIGURE 48 U.S. MARKET INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE
SECTORS, 2009-2016 ($ MILLIONS) 135
FIGURE 49 U.S. MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, 2009-2016
($ MILLIONS) 137
FIGURE 50 U.S. MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
2009-2016 ($ MILLIONS) 138
FIGURE 51 U.S. MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($ MILLIONS) 140
FIGURE 52 U.S. MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($ MILLIONS) 142
FIGURE 53 U.S. MARKET OF ENZYME INHIBITORS IN VARIOUS CANCER, 2009-2016 ($
MILLIONS) 144
FIGURE 54 U.S. MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016 ($
MILLIONS) 145
FIGURE 55 U.S. MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016 ($
MILLIONS) 147
FIGURE 56 NUMBER OF PATENTS BY YEAR, 2008–2012 149
FIGURE 57 NUMBER OF PATENTS BY YEAR, 2008-2012 (%) 150
FIGURE 58 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–2012 151
FIGURE 59 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,
2008–2012 154
FIGURE 60 PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008-2012 (%) 155
FIGURE 61 PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008–2012 (%) 156
To order this report:
Drug_and_Medication Industry: Global Markets for Enzyme Inhibitors -- Focus on the US
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article